Nephropathy News and Research

RSS

Nephropathy is a broad medical term used to denote disease or damage of the kidney, which can eventually result in kidney failure. The primary and most obvious functions of the kidney are to excrete any waste products and to regulate the water and acid-base balance of the body – therefore loss of kidney function is a potentially fatal condition.

Blood journal to publish Soliris study results in Paroxysmal Nocturnal Haemoglobinuria

The Canadian Association of PNH Patients welcomes the upcoming publication of a study that resoundingly proves the efficacy of Soliris, the first and only life-saving treatment for the ultra-rare blood disease known as Paroxysmal Nocturnal Haemoglobinuria.

11 Apr 2011

ALR announces medical research grant awards to cure lupus

The Alliance for Lupus Research – the world's largest private funder of lupus research – today announced its most recent medical research grant awards, totaling $3.6 million, which support the ALR mission of finding better treatments and ultimately preventing and curing systemic lupus erythematosus, a debilitating autoimmune disease.

7 Apr 2011

A2AAR-selective agonists may prevent permanent vision damage from traumatic optic nerve injury

Scientists want to protect the optic nerve when the eye takes a blow on the battlefield or in a car wreck.

7 Apr 2011

Scientists identify biological pathways that mediate IgA nephropathy

For the first time, researchers have found five regions in the human genome that increase susceptibility to immunoglobulin A nephropathy, a major cause of kidney failure worldwide - systematically identifying those that point to a tendency for IgA nephropathy, or a protection against it.

6 Apr 2011

Device to treat resistant hypertension lowers blood pressure by 33 points

A device designed to treat people with resistant hypertension helped lower blood pressure by 33 points, a substantial drop that would otherwise require patients to take an additional three or four drugs, on top of this subgroup's usual regimen of up to five drugs, to control their difficult-to-treat condition.

6 Apr 2011

PLC's RenalGuard REMEDIAL II trial against CIN presented at ACC.11

PLC Systems Inc., a company focused on innovative medical device technologies, announced that final results from the REMEDIAL II investigator-sponsored clinical trial of RenalGuard in Italy were presented today.

5 Apr 2011

Scientists reveal unknown role of cilia protein IFT88 in mitosis

Researchers at the University of Massachusetts Medical School have described a previously unknown role for the cilia protein IFT88 in mitosis, the process by which a dividing cell separates its chromosomes containing the cell's DNA into two identical sets of new daughter cells.

5 Apr 2011

KCP commends CMS for eliminating 'transition adjustment' imposed on new ESRD PPS

Kidney Care Partners, a broad-based coalition of patient advocates, dialysis professionals, care providers and manufacturers, commends the Centers for Medicare and Medicaid Services for eliminating the so-called "transition adjustment" imposed on dialysis facilities as part of the new Medicare end-stage renal disease prospective payment system.

2 Apr 2011

PLC's RenalGuard System REMEDIAL II trial final results to be presented at ACC conference

PLC Systems Inc., a company focused on innovative medical device technologies, today reported that final results from the REMEDIAL II investigator-sponsored clinical trial of its RenalGuard System™ in Italy are scheduled to be presented at 11:57 a.m. CT on Monday, April 4, 2011, at the American College of Cardiology's 60th Annual Scientific Session & Expo in New Orleans, Louisiana. Additionally, PLC will be demonstrating RenalGuard at its booth at the conference.

2 Apr 2011

New CMS reimbursement system for ESRD may place cost constraints on clinics

According to Millennium Research Group, the global authority on medical technology market intelligence, the new reimbursement system from the Centers for Medicare & Medicaid Services for end stage renal disease will have a mixed but mostly negative effect on the market for ESRD treatment devices.

1 Apr 2011

First Edition: April 1, 2011

Today's health policy news coverage helps fill in the details of the much-anticipated rule for accountable care organizations, which was released yesterday by the Obama administration.

1 Apr 2011

NIH-funded program to focus on obesity complications in low-income mothers

A Michigan State University nursing researcher has been awarded $3.3 million to help low-income mothers who are overweight or obese improve their health by eating well, being active and dealing with stress.

1 Apr 2011

CorMedix reports encouraging interim results from CRMD001 phase II study in Contrast Induced Acute Kidney Injury

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced its interim analysis and clinical update for CRMD001.

1 Apr 2011

Watson, GeneraMedix receive FDA approval for Nulecit to treat iron deficiency anemia

Watson Pharmaceuticals, Inc. today announced that it is initiating launch activities of Nulecit, following FDA approval of GeneraMedix Inc.'s, Abbreviated New Drug Application.

1 Apr 2011

Study: People who have survived diabetes for many decades exhibit few complications

Over time, diabetes can wreak havoc on the body's eyes, cardiovascular system, kidneys and nerves. A major study by Joslin Diabetes Center researchers, however, has found that some people who have survived diabetes for many decades exhibit remarkably few complications—a discovery that points toward the presence of protective factors that guard against the disease's effects.

31 Mar 2011

Could HIV-infected organs save 'lives?

Johns Hopkins researchers argue for reversing ban on transplanting infected organs and making them available to HIV-infected patients

30 Mar 2011

New study: Periodontal therapy can help reduce medical costs for patients with diabetes

The results from a new CIGNA study support that there is a potential association between treated periodontal disease and reduced medical costs for patients with diabetes.

30 Mar 2011

Metabolic Solutions initiates MSDC-0602 Phase 2a trial in patients with type 2 diabetes

Metabolic Solutions Development Company, a drug discovery and development company exploiting novel molecular targets to treat metabolic diseases, announced today that it has launched a Phase 2a trial for MSDC-0602, the company's second drug candidate for the treatment of type 2 diabetes.

30 Mar 2011

Concert initiates CTP-499 Phase 1 study in patients with diabetic nephropathy

Concert Pharmaceuticals, Inc. today announced it has made significant progress advancing CTP-499, its novel anti-inflammatory, anti-oxidant, and anti-fibrotic agent for diabetic nephropathy and other forms of chronic kidney disease, into clinical development.

29 Mar 2011

Interventional radiologists complete RDN human trial in patients with uncontrolled hypertension

Interventional radiologists have completed the first human randomized controlled trial of therapeutic renal denervation or RDN—a procedure that uses a catheter-based probe inserted into the renal artery that emits high-frequency energy to deactivate the nerves near the kidneys that are linked to high blood pressure.

29 Mar 2011

Nephropathy News and Research

Further Reading

Blood journal to publish Soliris study results in Paroxysmal Nocturnal Haemoglobinuria

ALR announces medical research grant awards to cure lupus

A2AAR-selective agonists may prevent permanent vision damage from traumatic optic nerve injury

Scientists identify biological pathways that mediate IgA nephropathy

Device to treat resistant hypertension lowers blood pressure by 33 points

PLC's RenalGuard REMEDIAL II trial against CIN presented at ACC.11

Scientists reveal unknown role of cilia protein IFT88 in mitosis

KCP commends CMS for eliminating 'transition adjustment' imposed on new ESRD PPS

PLC's RenalGuard System REMEDIAL II trial final results to be presented at ACC conference

New CMS reimbursement system for ESRD may place cost constraints on clinics

First Edition: April 1, 2011

NIH-funded program to focus on obesity complications in low-income mothers

CorMedix reports encouraging interim results from CRMD001 phase II study in Contrast Induced Acute Kidney Injury

Watson, GeneraMedix receive FDA approval for Nulecit to treat iron deficiency anemia

Study: People who have survived diabetes for many decades exhibit few complications

Could HIV-infected organs save 'lives?

New study: Periodontal therapy can help reduce medical costs for patients with diabetes

Metabolic Solutions initiates MSDC-0602 Phase 2a trial in patients with type 2 diabetes

Concert initiates CTP-499 Phase 1 study in patients with diabetic nephropathy

Interventional radiologists complete RDN human trial in patients with uncontrolled hypertension

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News